Podcasts about BMI

Country Music Hall of Famer, Nashville Songwriters Hall of Famer, 2-time Country Song of the Year GRAMMY winner, and 5-time BMI Country Songwriter of the Year Paul Overstreet gives us a peek behind the curtain of his legendary career. PART ONE: Scott does his best not to throw a certain individual under the bus with a very funny story involving Paul Overstreet. Plus, the guys pay tribute to the late Joe Melson, past Songcraft guest and primary Roy Orbison collaborator. PART TWO: Our in-depth conversation with Paul OverstreetABOUT PAUL OVERSTREET Paul Overstreet is one of the most successful songwriters in Nashville history and among the three inductees in the Country Music Hall of Fame's class of 2026. His catalog of classics includes “Same Ole Me,” recorded by George Jones, as well as the Randy Travis hits “Digging Up Bones,” “No Place Like Home,” “Deeper Than the Holler,” “On the Other Hand,” and “Forever and Ever, Amen.” The latter two were both named Song of the Year by NSAI, the CMA, and the ACM. Additionally, “Forever and Ever, Amen” earned a Grammy award for Best Country Song in 1988. Overstreet won another Best Country Song Grammy in 1992 for “Love Can Build a Bridge,” which was a major hit for The Judds.  Other highlights of the Paul Overstreet songbook include the number one hits “A Long Line of Love,” recorded by Michael Martin Murphy,” “When You Say Nothing at All,” which was a hit for both Keith Whitley and Alison Krauss, and “Some Beach” for Blake Shelton. In addition to his achievements with other performers, Overstreet became a successful recording artist in his own right. He reached the top of the charts in 1987 with “I Won't Take Less Than Your Love,” which he recorded with Tanya Tucker and Paul Davis, and had hits with the group S-K-O, a trio he formed with Thom Schuyler and Fred Knobloch. From 1988 through 1991 Paul scored eight consecutive top 10 singles as a solo artist, including “Seein' My Father in Me” and “Daddy's Come Around.”  Paul was named BMI's Country Songwriter of the year five years in a row from 1987 through 1991, a feat that hasn't been duplicated since. He was inducted into the Nashville Songwriters Hall of Fame in 2003.    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why is your fat talking to you?In the latest solo episode, Dr. Emily Cooper, Andrea Taylor, and Mark Wright explore groundbreaking research into metabolic health. Learn why the scale doesn't always reflect metabolic risk, and discover the science behind fat's active role in the body. KEY TAKEAWAYSMetabolic dysfunction cannot be judged by scale weight alone.Visceral fat is a stronger predictor of heart failure than BMI.Hormonal environments profoundly affect fat storage and health risks.NOTABLE QUOTE"Your fat is talking to you." — Andrea TaylorLINKS & RESOURCESObesity Reviews PaperImmunological Reviews Journal ArticleEuropean Congress on Obesity Study Links & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you ever been in and out of hospital so many times that everyone around you quietly stopped believing you'd ever get better, so you started to believe it too? This episode is for you."This week on the Full of Beans Podcast, I'm joined by Hannah Whitfield, a creative activist, writer, speaker, performer and founder of Legally Detained - a lived-experience-led creative platform transforming survival into power through art, activism and unapologetic storytelling. Her work explores neurodivergence, trauma, mental health systems, eating disorder recovery, inclusion and the power of creative expression. Through speaking, writing, performance, consultancy and her podcast No Longer Legally Detained, Hannah challenges systems that ask people to become smaller to survive, and instead creates work that says: we were never broken - we were surviving worlds that were never built with us in mind.In this episode, we explore:Where Legally Detained came fromHannah's experience of psychiatric admissionsBeing placed on a ward that didn't believe her eating disorder was "real" Becoming a "revolving door patient" across CAMHS, adult services, and secure careThe problem with BMI criteria as a gatekeeper for treatmentWhere restrictive practice crosses the line from safety into crueltyThe rock-bottom moment that changed everythingHow an ADHD diagnosis helped Hannah understand her own patterns for the first timeReframing recovery: it's not a "utopia," it's learning to ride the waveWhy purpose and belonging, not just words, are what help people recoverConnect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTubeConnect with Hannah via Instagram @legallydetained, her website, blog, or podcast: No Longer Legally Detained. ⚠️ Content Note: This episode contains discussions of eating disorder treatment, inpatient care, and iatrogenic harm. Please take care of yourself while listening.

Wykład lek. Maciej Walędziaka w ramach w ramach XII Dnia Odkrywców Kampusu Ochota Uniwersytetu Warszawskiego [21 marca 2026 r.]Otyłość nie jest wyłącznie skutkiem braku silnej woli ani prostym problemem nadmiaru spożywanych kalorii. To przewlekła, złożona choroba, na której rozwój wpływają czynniki biologiczne, hormonalne, genetyczne, psychologiczne, społeczne i środowiskowe.Lek. Maciej Walędziak wyjaśnia, jak współczesna medycyna podchodzi do leczenia otyłości. Pokazuje, dlaczego samo zalecenie „proszę mniej jeść i więcej się ruszać” często okazuje się niewystarczające oraz dlaczego skuteczna terapia powinna być dostosowana do sytuacji konkretnego pacjenta.Punktem wyjścia jest właściwe rozpoznanie choroby i ocena jej wpływu na zdrowie. Znaczenie mają nie tylko masa ciała i wskaźnik BMI, lecz także rozmieszczenie tkanki tłuszczowej, obwód talii, występowanie chorób współistniejących oraz dotychczasowe próby redukcji masy ciała.Otyłość zwiększa ryzyko wielu poważnych problemów zdrowotnych, między innymi cukrzycy typu 2, nadciśnienia tętniczego, chorób układu krążenia, bezdechu sennego, przeciążenia stawów, stłuszczenia wątroby i niektórych nowotworów. Może również wpływać na sprawność, samopoczucie psychiczne, relacje społeczne i jakość życia.Podstawą terapii pozostaje trwała zmiana sposobu odżywiania i codziennych nawyków. Nie chodzi jednak o krótkotrwałą, restrykcyjną dietę, lecz o stopniowe wprowadzanie rozwiązań, które pacjent jest w stanie utrzymać przez długi czas. Ważną rolę odgrywają również aktywność fizyczna, sen, ograniczenie stresu i praca nad mechanizmami sprzyjającymi nadmiernemu jedzeniu.Leczenie otyłości może wymagać współpracy wielu specjalistów: lekarza, dietetyka, psychologa, fizjoterapeuty, a w niektórych przypadkach także chirurga. W zależności od stopnia zaawansowania choroby i stanu zdrowia pacjenta stosuje się leczenie zachowawcze, farmakologiczne lub operacyjne.Farmakoterapia może wspierać redukcję masy ciała poprzez wpływ na apetyt, uczucie sytości i procesy metaboliczne. Nie zastępuje jednak zmiany stylu życia i powinna być prowadzona pod kontrolą lekarza. Dobór leczenia zależy od wskazań, przeciwwskazań, chorób współistniejących i reakcji pacjenta na terapię.Jedną z metod leczenia zaawansowanej otyłości jest chirurgia bariatryczna. Zabiegi bariatryczne nie polegają wyłącznie na mechanicznym zmniejszeniu żołądka. Wpływają także na wydzielanie hormonów regulujących głód, sytość i metabolizm. Mogą prowadzić do znacznego zmniejszenia masy ciała oraz poprawy lub ustąpienia części chorób związanych z otyłością.Operacja nie jest jednak rozwiązaniem automatycznym ani drogą na skróty. Wymaga odpowiedniej kwalifikacji, przygotowania, zmiany sposobu odżywiania, regularnych kontroli i długotrwałej współpracy pacjenta z zespołem medycznym.Wykład zwraca również uwagę na problem stygmatyzacji osób chorujących na otyłość. Obwinianie pacjenta, zawstydzanie go lub sprowadzanie choroby do braku dyscypliny może utrudniać rozpoczęcie leczenia i pogarszać jego skuteczność. Otyłość powinna być traktowana jak inne choroby przewlekłe – z empatią, szacunkiem i wykorzystaniem dostępnych metod terapeutycznych.Czy otyłość można skutecznie leczyć? Jak wybrać odpowiednią metodę? Kiedy wystarczy zmiana nawyków, a kiedy potrzebne są leki lub zabieg chirurgiczny? Wykład pokazuje, że terapia jest możliwa, ale powinna być kompleksowa, indywidualna i nastawiona na długofalową poprawę zdrowia, a nie wyłącznie na liczbę kilogramów.Wykład lek. Macieja Walędziaka odbył się w ramach Dnia Odkrywców Kampusu Ochota Uniwersytetu Warszawskiego.#MaciejWalędziak #Otyłość #LeczenieOtyłości #ChorobaOtyłościowa #Bariatria #ChirurgiaBariatryczna #Odchudzanie #ZdroweOdżywianie #Zdrowie #Dietetyka #AktywnośćFizyczna #Farmakoterapia #Cukrzyca #Insulinooporność #ZdrowieMetaboliczne #Medycyna #KampusOchota #UniwersytetWarszawski #DzieńOdkrywców #Wszechnica

A recent study made headlines for claiming a ketogenic diet may worsen fatty liver disease and raise triglycerides. But when you take a closer look at the research, it's clear that the conclusions are far less supported than the coverage suggests.To clear things up, Dr. Bret Scher breaks down what the study actually found, where the methodology falls short, and what the broader body of research has to say about ketogenic therapy and liver health.In this discussion, you'll learn:What the study examined and how the data was collectedWhy the lack of ketone measurement makes it impossible to confirm anyone was actually in ketosisHow reverse causality may explain the findings entirelyWhat baseline differences in BMI and adiposity reveal about the study populationWhy cross-sectional observational studies sit lower on the evidence hierarchy than RCTsWhat a meta-analysis of 62 randomized controlled trials shows about ketogenic diets and triglyceridesWhat a 12-week supervised intervention revealed about ketogenic therapy and fatty liver reductionWhy higher-quality controlled trial evidence should take precedence over headline-grabbing observational studiesFor clinicians, researchers, and anyone navigating conflicting headlines about ketogenic therapy, this conversation is a reminder that the quality of evidence matters as much as the findings themselves.

"In honor of America's 250th anniversary, A Great Awakening tells the true story of an unlikely friendship that resulted in one of the most defining moments in American history.  With the colonies on the brink of collapse, the Reverend George Whitefield (Jonathan Blair) sparks the first Great Awakening, uniting an entire generation with his thundering proclamation of liberty in Christ. In a miraculous turn of events, one of Whitefield's closest friends and greatest promoters becomes none other than Benjamin Franklin (John Paul Sneed). With the nation's freedom hanging in the balance, Franklin discovers true liberty cannot only be written into law - it must be awakened in the hearts of the people."   You can watch A Great Awakening now through the Wonder Project subscription on Prime Video!   For more information about The Collision, click here: https://thecollision.org/   TIMESTAMPS 0:00 Introduction 2:05 Leadership Trivia 2:55 Discussing A Great Awakening 35:08 Leadership Trivia Response   Questions or comments? Email us at podcast@blackaby.org   DONATE: If you have enjoyed this podcast and want to support our ministry into the next 20 years, click here: https://bit.ly/382Exi3   RESOURCES: Sign up for the monthly newsletter at the bottom of the BMI homepage: https://blackaby.org/   Sign up for Fall Coaching Workshop here: https://www.blackabycoaching.org/workshop   Order Experiencing God in Everyday Life now at: https://www.lifeway.com/en/product/experiencing-god-in-everyday-life-bible-study-book-with-video-access-P005853831   CONNECT: X: @richardblackaby Facebook: https://bit.ly/2WvZPzw Read Richard's latest blog posts at www.richardblackaby.com

The fastest way to change your glucose numbers might not be another food rule. It might be muscle. Today, we get practical about strength training and why it's a foundational lever for metabolic health, weight loss results, and better day-to-day energy.I'm joined by Signos' clinical lead and scientific advisor, Dr. Gray Strike, who has a PhD in nutrition and exercise physiology. We start by dismantling the fear that lifting automatically makes you bulky, then define what resistance training actually is: challenging your muscles against a force with progressive overload over time. We even run through common workouts people ask about, from bands and bodyweight to Pilates-style classes, to clarify what truly builds strength.From there, we connect the dots to glucose control. Dr. Strike explains why muscle acts like a sponge for glucose, how exercise can improve insulin sensitivity, and why muscle glycogen storage matters when you're trying to reduce spikes on a continuous glucose monitor (CGM). We also zoom out to the bigger picture: mental health, sleep, longevity, and the real-world abilities strength protects as you age.Finally, we address weight management myths and the GLP-1 movement. If the scale rises when you start lifting, we explain what to track instead, why body composition beats BMI, and why preserving lean mass is critical, especially for anyone using GLP-1 medications. Press play for a simple, low-pressure plan to start with bodyweight at home and build from there, then subscribe, share this with a friend who “hates lifting,” and leave a review so more people can find the show.Click Here to pre-order a copy of my new book The Glucose Edge. 

It's been a while. Thank you for sticking with us while we've been gone.Dozens of countries have started taxing sugary drinks over the last couple of decades. You can see the reasoning: if they cost companies more to make, then companies will pass that cost on to consumers, who will buy less, and hopefully get less fat and then die less often of diabetes and heart disease.But does that actually work? We had a look at the studies behind it.This podcast is sponsored by Works in Progress magazine. Find endless fascinating pieces on human progress at worksinprogress.co.Show notes* Germany's planned tiered sugar levy — the announcement (and a bit more detail on the €0.26/€0.32-per-litre thresholds)* The WHO's Global report on the use of sugar-sweetened beverage taxes, 2025* The World Bank's Global SSB Tax Database, the source for the “100+ jurisdictions” figure* Chris Snowdon / IEA's case against sugar taxes: the classic Sugar Taxes: A Briefing and, more recently, The bitter truth about the sugar tax in The Critic* Andreyeva et al.'s 2022 meta-analysis in JAMA Network Open.* Scarborough et al.'s 2020 PLOS Medicine paper on UK reformulation.* The UK Government's November 2025 Strengthening the Soft Drinks Industry Levy consultation* The substitution question:* 2021 Seattle study (difference-in-difference vs Portland; drinks sugar down, sweets up a bit)* 2025 Chinese modelling paper (the +2.57% total-calorie result in low-income families)* The IZA discussion paper on the UK levy (no substitution to other sweet drinks)* The modelling studies:* 2017 Mexico paper (86–134k diabetes cases “prevented” by 2030)* Scarborough et al.'s 2024 PLOS Medicine PRIMEtime model* Sánchez-Romero et al.'s 2016 PLOS Medicine Markov cohort simulation * The direct, empirical outcome studies:* The 2024 Philadelphia BMI study (the one that found only six prior studies; null panel sample)* The 2025 California study (small effects, wide error bars)* The Mauritius study (no significant BMI association)* The big one — Rogers et al.'s 2023 PLOS Medicine interrupted time series on English schoolchildren (the 8% relative reduction in year 6 girls; 5,234 cases “prevented”)* Chris Snowdon's demolition of it, including the 2013–2018 counterfactual buried in the supplementary material* Gallup on the recent US obesity decline coinciding with GLP-1 drugsCreditsThe Science Fictions podcast is produced by Julian Mayers at Yada Yada Productions. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit sciencefictionspod.substack.com/subscribe

Some of you may know that I'm a Board Certified Patient Advocate. I don't currently do a lot of individual advocacy because my speaking schedule doesn't allow for the necessary time availability so I typically either work on complex or emergency cases, or on cases that are not strictly timebound - most of these are people who are dealing with a BMI-based denial of care, meaning that their healthcare is being held hostage for a weight loss ransom. This is one of those situations and I am, as always, sharing this story with permission and anonymously by request. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Witam Państwa, nazywam się Jarosław Drożdż, pracuję w Centralnym Szpitalu Klinicznym Uniwersytetu Medycznego w Łodzi, skąd nagrywam podcast Kardio Know-How. W tym odcinku omawiam wpływ leczenia otyłości na choroby sercowo-naczyniowe. Po dekadach nieskutecznych prób leczenia otyłości dysponujemy dziś dwiema metodami, które wykazały wyraźne korzyści kliniczne: chirurgią bariatryczną oraz agonistami receptora GLP-1. Chirurgia bariatryczna, mimo ponad 50-letniej historii i braku badań randomizowanych, w dużych badaniach obserwacyjnych zmniejsza śmiertelność całkowitą o 38%, a sercowo-naczyniową aż o 50%, a także istotnie ogranicza częstość hiperlipidemii, choroby wieńcowej, żylnej choroby zakrzepowo-zatorowej i niewydolności serca. Potwierdza to metaanaliza 18 badań obejmująca 270 tys. operowanych i 1,2 mln nieoperowanych pacjentów z otyłością (średnie BMI >40). https://pmc.ncbi.nlm.nih.gov/articles/PMC7386646/ Agoniści GLP-1, przede wszystkim semaglutyd, są natomiast pierwszą grupą leków przeciw otyłości z przekonującymi dowodami z badań randomizowanych. Ich działanie wykracza poza redukcję masy ciała – poprzez pobudzenie receptora GLP-1 poprawiają kontrolę glikemii, metabolizm lipidów, zmniejszają stan zapalny i wywierają korzystny wpływ na układ sercowo-naczyniowy. Co szczególnie istotne, korzyści kliniczne, zwłaszcza redukcja powikłań sercowo-naczyniowych, pojawiają się wcześniej niż wyraźny spadek masy ciała, co wskazuje, że kluczowe znaczenie ma samo pobudzenie receptora GLP-1. Autor artykułu Heart, Carel le Roux, porównuje tę zmianę do rewolucji, jaką przyniosły statyny – zamiast koncentrować się wyłącznie na ograniczaniu jedzenia, coraz częściej leczymy biologiczne mechanizmy odpowiedzialne za otyłość. Już u osób z BMI ≥27, a więc jeszcze przed rozpoznaniem otyłości, wykazano zmniejszenie liczby powikłań, zwłaszcza u chorych z niewydolnością serca z zachowaną frakcją wyrzutową (HFpEF). W badaniach STEP-HFpEF śmiertelność u chorych z cukrzycą typu 2 zmniejszyła się z 3% do 2%, natomiast w badaniach SELECT i FLOW osiągnęła około 20% redukcji w ciągu kilku lat. Wszystko wskazuje na to, że agoniści GLP-1 mogą w najbliższych latach stać się, podobnie jak statyny, jednym z filarów prewencji i leczenia chorób sercowo-naczyniowych.Szczegółowy TRANSKRYPT do odcinka.Podcast jest przeznaczony wyłącznie dla osób z profesjonalnym wykształceniem medycznym.

"The idea of metabolic scoring is to take guilt out of the picture. Because this is not anyone's fault. It's basically a cosmic shift in just our whole lifestyle here in Western civilization." — Dr. Ron HunninghakeIn this episode of the Real Health Podcast, Dr. Ron Hunninghake and Dr. Drew Rose discuss the complexities of metabolic syndrome, its prevalence in the Western world, and the lifestyle factors contributing to it. They emphasize the importance of identifying root causes and implementing personalized health strategies to combat this growing epidemic.

Have you ever sat in a treatment room and felt like the real you was completely invisible, like the system was so focused on your weight, your behaviours, your diagnosis, that it forgot there was a whole person underneath? This episode is for you.This week on the Full of Beans Podcast, I'm joined by Tanya Francis, a research psychologist, lecturer at the Open University, and psychotherapist in private practice, who also brings her own lived experience of an eating disorder to this conversation.Tanya's background is in domestic violence research and gender-based violence, and the more she looked at how systems respond when someone is harmed, the more she saw uncomfortable parallels with eating disorder care.In this episode, we explore:What iatrogenic harm means and why care systems can sometimes cause harmThe role of BMI and weight in treatment,How rigid care centralising numbers can reinforce eating disorder logicHow weight stigma in healthcare shuts people out before they've even begunThe culture of mistrust around eating disorders and the damage it doesWhy people pleasing in treatment can look like recovery but lead straight back to relapseMoral injury and what happens when clinicians can't act on their own valuesTanya's own experience of not being believed in her body during inpatient careWhy truly humanising care is both simpler and more complex than it soundsHow two things can be true at once, e.g. a broken system and incredible people working within itConnect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTubeConnect with Tanya via Instagram (@drtanyafrances), LinkedIn or her website⚠️ Content Note: This episode contains discussions of eating disorder treatment, inpatient care, and iatrogenic harm. Please take care of yourself while listening.

Welcome to the latest from Studio "V". The "4 DIFFERENT WORLDS" Episode for the four different rhythm grooves on each song. Our feature song for the set is "THE JUNE, MOON AND SPOON OF IT ALL" We think you'll like it!  Ttitles: "IN THE IMAGE", "EVERY WORD OF IT", feature song "THE JUNE, MOON, AND SPOON OF IT ALL" and "A CLEAR & GOOD FEELING". {COMPLIMENTS OF COSMIC CONSCIOUSNESS MUSIC ©2026 BMI}. Enjoy!

Can Medicare patients get GLP-1 medications like Wegovy and Zepbound for $50 per month through the new Medicare GLP-1 Bridge Program?In this episode, Zoe is joined by Dr. Matthew Weiner and Deidre, FNP, to break down what Medicare patients need to know about the CMS Medicare GLP-1 Bridge Program. They explain who may qualify, why Medicare Part D coverage matters, and why the process is more complicated than simply getting a prescription.Deidre walks through the eligibility requirements, including BMI, prediabetes, cardiovascular disease, uncontrolled hypertension, sleep apnea, diabetes, and fatty liver disease. She also explains why some patients may not be able to use the Bridge Program if their GLP-1 medication can already be covered through their regular Medicare Part D benefits.They also discuss the two-step prior authorization process, the $50 monthly copay, why that copay may not count toward a deductible, and why documentation for a structured nutrition and lifestyle program is required.Most importantly, the team explains what patients should realistically expect as the program rolls out, why delays and confusion are likely at first, and how Pound of Cure is preparing to help eligible Arizona patients navigate access to GLP-1 medications.

Wylecz Insulinooporność!---W tym odcinku tłumaczymy, dlaczego insulinooporność oraz hiperinsulinemia są kluczowymi przyczynami większości chorób metabolicznych. W programie podważane są tradycyjne zalecenia systemowe, takie jak liczenie kalorii czy klasyczna piramida żywienia, na rzecz edukacji i prawdziwej profilaktyki.W tym odcinku usłyszysz:·       Przełom prof. Josepha Crafta – O tym, jak badanie poziomu insuliny (a nie tylko glukozy) pozwala wykryć zaburzenia metaboliczne nawet 15 lat przed rozwinięciem się cukrzycy.·       Dlaczego wskaźnik BMI jest wadliwy – Jak tradycyjne podejście pomija osoby szczupłe, ale chore metabolicznie (tzw. TOFI).·       Analiza krzywych insulinowych na żywo – Interpretacja konkretnych wyników przesłanych przez widzów, pokazująca m.in. błędy w interpretacji laboratoryjnej oraz wzorce ukrytej hiperinsulinemii.·       Historie i telefony pacjentów:o   Rozmowa z Łukaszem, który dzięki diecie keto schudł 18 kg w miesiąc i pyta, jak bezpiecznie utrzymać wagę.o   Telefon od Justyny z Irlandii w sprawie męża od 15 lat chorującego na cukrzycę typu 2, przyjmującego m.in. insulinę i leki stymulujące trzustkę, dla którego Bracia szukają wsparcia lekarskiego online. Odcinek pokazuje, jak ogromną rolę w powrocie do zdrowia odgrywa eliminacja węglowodanów oraz naturalna regulacja hormonów sytości (takich jak GLP-1) poprzez odpowiednie odżywianie.Wskakuj na naszą stronę https://braciarodzen.pl/wakacje-z-bracmi-rodzen/ i zapisz się do tej akcji czeka na Ciebie mnóstwo wiedzy slajdy oraz praktyczne prezenty. Słuchajcie nas regularnie we wtorki, środy i czwartki o 21:00. Subskrybujcie podcast, zostawcie łapkę w górę, udostępniajcie i do zobaczenia w kolejnym odcinku! Akcja Wylecz Insulinooporność! -  pod patronatem: Polskiego Towarzystwa Leczenia Insulinooporności!https://ptli.pl/ ====Ważne: Nasz podcast może być emitowany z opóźnieniem w stosunku do odcinków na żywo. Promocje i informacje o wydarzeniach mogą być nieaktualne. Aktualne informacje znajdziesz na naszej stronie lub innych kanałach – linki poniżej.====Jeśli to, co robimy, jest dla Ciebie wartościowe, spraw, aby inni mogli to odkryć – udostępnij ten podcast i zostaw ocenę! ⭐⭐⭐⭐⭐ Twoja opinia ma znaczenie i pomaga nam docierać do kolejnych osób, które potrzebują tej wiedzy. Dziękujemy za Twoje wsparcie!Dołącz do NIEZALEŻNIE MYŚLĄCEJ i pięknie żyjącej społeczności

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Graham walked out of his endocrinologist appointment with two things nobody saw coming — a brand new insulin delivery patch and an Ozempic prescription. Ken had questions. A lot of them.First up is the CEQUR Simplicity insulin patch — a band-aid sized device that holds up to 200 units of insulin and delivers two units per click. No app, no screen, no tubing. Just insulin on your body, ready when you need it. Ken and Graham break down who this actually makes sense for and how it fits into a real insulin management strategy.Then comes the Ozempic conversation. Ken digs into what GLP-1 medications actually do biologically in Type 1 diabetes, why the way they're being marketed to the public is dangerously oversimplified, and why the reason you're taking it matters just as much as the medication itself.And somewhere in between — BMI. Why Ken thinks it's one of the most misleading metrics in medicine, and what should actually be happening at the point of a diabetes diagnosis.Two Type 1 diabetics. Nearly 50 years of lived experience. Zero sugarcoating.

Medicare's new GLP-1 Bridge Program gives eligible retirees access to Wegovy and Zepbound for $50 a month — but there are three financial catches worth knowing before you enroll.In this episode of the Secure Your Retirement Podcast, Radon and Murs discuss one of the biggest Medicare developments of 2026 — the new GLP-1 Bridge Program, launching July 1, which allows eligible Medicare beneficiaries to access popular GLP-1 weight loss medications like Wegovy and Zepbound for a flat $50 copay per month. Joined by Peace of Mind Wealth Management's in-house Medicare specialist Sean Southard, they break down exactly what this program is, who qualifies, how the approval process works, and what the financial implications look like for retirees on fixed incomes.Listen in to learn about the three financial angles every retiree needs to understand before enrolling in the GLP-1 Bridge Program, including why that $50 copay sits completely outside your normal Medicare Part D protections, what happens when the program ends in December 2027, and how GLP-1 medications and Medicare prescription drug coverage fit into a broader retirement planning conversation around healthcare costs, budgeting, and long-term affordability.In this episode, find out:What GLP-1 medications are, why Medicare historically excluded them for weight loss, and what changed in 2026 to make the GLP-1 Bridge Program possibleWho qualifies for the program based on BMI and health conditions, and how your doctor submits a prior authorization request through Medicare's centralized systemWhy the $50 flat copay does not count toward your Medicare Part D deductible or annual out-of-pocket maximum, and what that means for your retirement budgetWhat retirees need to plan for when the program's temporary status ends in December 2027 and costs could jump significantlyThe health considerations and side effects of GLP-1 medications that matter most for older adults, and why this conversation belongs with your doctor and your financial plannerTweetable Quotes:"Retirees need to avoid assuming that this benefit program is going to be permanent forever. Plan for what happens if that $50 copay jumps back up to several hundred dollars a month." — Murs Tariq"This is both a healthcare conversation and a financial planning conversation. Retirees should evaluate long-term affordability, potential future coverage changes, and how chronic disease management fits into an overall retirement plan." — Shawn SouthardResources:If you are in or nearing retirement and you want to gain clarity on what questions you should be asking, learn what the biggest retirement myths are, and identify what you can do to achieve peace of mind for your retirement, get started today by requesting our complimentary video course, Four Steps to Secure Your Retirement!To access the course, simply visit POMWealth.net/podcast.

In this episode of Liz on Biz, Liz Theresa interviews Dr. Meghan Garcia-Webb, an obesity and weight medicine specialist based in Boston. Dr. Garcia-Webb shares her journey from primary care to founding her private practice, focusing on compassionate, individualized care for those struggling with weight at any BMI. Together, they discuss the limitations of BMI, the influence of diet culture, sustainable approaches to health, weight loss medications, and the importance of self-acceptance and boundaries—plus practical tips for building a healthier relationship with both food and time.Meghan Garcia-Webb, MD is triple board-certified in internal medicine, lifestyle medicine, and obesity medicine. She produces a weekly YouTube series, “Weight Medicine with Dr. Meghan MD,” and provides life coaching to help people fix the One Big Thing blocking their weight loss. Her innovative private practice (www.weightmedicinemd.com) combines concierge weight medicine with life coaching, and she is also an internist at an academic medical center in Boston, MA. Hosted on Acast. See acast.com/privacy for more information.

We break down Medicare's brand-new GLP-1 Bridge Program and explain why headlines are both true and incomplete. We lay out the real eligibility rules, the $50 copay promise, and the smarter questions to ask so you and your clinician can find the right coverage pathway. • why Medicare historically excludes weight loss medications and what changed with modern obesity medicine • what the GLP-1 Bridge Program is designed to do and why it is not universal coverage • the $50 copay detail and why office visits labs and deductibles can still affect total cost • who does not qualify because another Medicare Part D pathway may already apply • the three eligibility “doors” based on BMI and specific risk conditions • which GLP-1 medications are included at the time of recording and the planned program timeline • how to prepare for an appointment and the exact phrasing that helps your clinician pick the right route • why checking CMS and staying current matters as rules evolve You can send us an email, you can find us on Threads, follow us on Instagram, or leave us some fan mail.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Join our Hernia Team for a review of the current controversy around preoperative optimization and the practical implications.Hosts: Dr. Maggie Bosley - @MBosleyMD Dr. Sean Orenstein - @OrensteinSean Dr. Amber Sandoval Dr. Peter Ferrin Institution: Oregon Health & Science UniversityReferences:Adverse Events after Ventral Hernia Repair: The Vicious Cycle of Complicationshttps://pubmed.ncbi.nlm.nih.gov/26206646/Risk factors for postoperative wound infections and prolonged hospitalization after ventral/incisional hernia repairhttps://pubmed.ncbi.nlm.nih.gov/24030572/lack of association between glycated hemoglobin and adverse outcomes in diabetic patients undergoing ventral hernia repair: an ACHQC studyhttps://pubmed.ncbi.nlm.nih.gov/35969297/Impact of preoperative haemoglobin A1c levels on postoperative outcomes in adults undergoing major noncardiac surgery: A systematic reviewhttps://pubmed.ncbi.nlm.nih.gov/38853752/Does active smoking really matter before ventral hernia repair? An AHSQC analysishttps://pubmed.ncbi.nlm.nih.gov/30220485/Abstinence from smoking reduces incisional wound infection: a randomized controlled trialhttps://pubmed.ncbi.nlm.nih.gov/12832959/The Association of Nicotine Replacement Therapy With Outcomes Among Smokers Hospitalized for a Major Surgical Procedurehttps://pubmed.ncbi.nlm.nih.gov/31790653/Is weight trajectory a better marker of wound complication risk than BMI in hernia patients with obesity?https://pubmed.ncbi.nlm.nih.gov/38082008/Gender, racial, and socioeconomic disparity of preoperative optimization goals in ventral hernia repairhttps://pubmed.ncbi.nlm.nih.gov/37658198/Limited or Lasting: Is Preoperative Weight Loss as Part of Prehabilitation Maintained after Open Ventral Hernia Repair?https://pubmed.ncbi.nlm.nih.gov/39907236/The impact of preoperative optimization for abdominal wall reconstruction on long-term glucose control and smoking cessationhttps://pubmed.ncbi.nlm.nih.gov/40739418/Watchful waiting as a treatment strategy for patients with a ventral hernia appears to be safehttps://pubmed.ncbi.nlm.nih.gov/26838293/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Many women are prescribed oral estrogen without ever being told what happens after it enters the body. In this episode, Dr. Brendan McCarthy takes a deeper look at estrone, the estrogen metabolite created when estradiol is taken orally, and explains why the delivery method of hormone therapy matters. You'll learn: The difference between estradiol and estrone Why oral estrogen creates significantly higher estrone levels How estrone may contribute to inflammation and insulin resistance The connection between estrogen metabolism and weight gain during perimenopause and menopause Why monitoring labs is essential when using hormone therapy The importance of understanding risks, benefits, and treatment options before starting hormones Dr. McCarthy also discusses the role of inflammation, body fat, metabolic health, and hormone delivery systems in creating long-term outcomes for women navigating menopause. This episode is about education, informed consent, and helping women better understand the science behind their care.   Citations: There is more than one estrogen; after menopause, estrone dominates Kuhl, Herbert. “Pharmacology of Estrogens and Progestogens: Influence of Different Routes of Administration.” Climacteric, vol. 8, no. S1, 2005, pp. 3–63. Body fat is an endocrine organ — aromatase converts androstenedione into estrone, and adipose becomes the dominant post-menopausal estrogen source Lee, Angel A., and Laura J. Den Hartigh. “Metabolic Impact of Endogenously Produced Estrogens by Adipose Tissue in Females and Males across the Lifespan.” Frontiers in Endocrinology, vol. 16, 2025, article 1682231. Inflamed fat raises IL-6; IL-6 tracks the insulin-resistant state Kern, Philip A., et al. “Adipose Tissue Tumor Necrosis Factor and Interleukin-6 Expression in Human Obesity and Insulin Resistance.” American Journal of Physiology-Endocrinology and Metabolism, vol. 280, no. 5, 2001, pp. E745–E751. IL-6 is part of the insulin-resistance machinery — it correlates with impaired insulin-stimulated glucose uptake Bastard, Jean-Philippe, et al. “Adipose Tissue IL-6 Content Correlates with Resistance to Insulin Activation of Glucose Uptake Both In Vivo and In Vitro.” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 5, 2002, pp. 2084–2089. Inflammation amplifies aromatase — IL-6 raises aromatase via COX-2/PGE2 Bowers, Laura W., et al. “Obesity-Associated Systemic Interleukin-6 Promotes Pre-Adipocyte Aromatase Expression via Increased Breast Cancer Cell Prostaglandin E2 Production.” Breast Cancer Research and Treatment, vol. 149, no. 1, 2015, pp. 49–57. Human-tissue confirmation: HOMA-IR, IL-6, insulin, leptin, hsCRP track breast aromatase after menopause Brown, Kristy A., et al. “Menopause Is a Determinant of Breast Aromatase Expression and Its Associations with BMI, Inflammation, and Systemic Markers.” The Journal of Clinical Endocrinology & Metabolism, vol. 102, no. 5, 2017, pp. 1692–1701. Iyengar, Neil M., et al. “Effects of Obesity on Breast Aromatase Expression and Systemic Metabo-Inflammation in Women with BRCA1 or BRCA2 Mutations.” npj Breast Cancer, vol. 7, no. 1, 2021, article 18. The molecular crux: estrone drives ERα/NF-κB inflammatory signaling while estradiol opposes it Qureshi, Rehana, et al. “The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven Mammary Inflammation and Breast Cancer Development.” Cell Metabolism, vol. 31, no. 6, 2020, pp. 1154–1172.e9. Estrone as a metabolic-risk signal — prospectively associated with diabetes (note: male cohort) Jasuja, Guneet Kaur, et al. “Circulating Estrone Levels Are Associated Prospectively with Diabetes Risk in Men of the Framingham Heart Study.” Diabetes Care, vol. 36, no. 9, 2013, pp. 2591–2596.   Dr. Brendan McCarthy is the founder and Chief Medical Officer of Protea Medical Center in Arizona. With over two decades of experience, he's helped thousands of patients navigate hormonal imbalances using bioidentical HRT, nutrition, and root-cause medicine. He's also taught and mentored other physicians on integrative approaches to hormone therapy, weight loss, fertility, and more. If you're ready to take your health seriously, this podcast is a great place to start.

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.We discuss:✅ Medicare Bridge Program eligibility requirements✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates✅ BMI and comorbidity qualifications✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access✅ How Medicare patients can obtain GLP-1 medications✅ Why obesity is finally being treated as a chronic disease✅ The future of obesity medicine and Medicare coverage✅ Concerns about access to care vs access to medication✅ Muscle loss, nutrition, strength training, and healthy weight loss✅ The Treat and Reduce Obesity Act (TROA)This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.

This episode of the Dr. Joe Galati podcast discussed the top 7 strategies to reduce your chance of #cancer.Avoiding tobaccoTobacco use remains the leading preventable cause of cancer. This includes cigarettes, cigars, pipes, vaping, and smokeless products. Chemicals in tobacco damage DNA and cause cancers of the lung, mouth, throat, esophagus, bladder, pancreas, and more. Quitting at any age significantly lowers risk, with benefits appearing within weeks.Maintaining a healthy weightExcess body fat increases inflammation and hormone levels linked to at least 13 cancers, including breast, colorectal, endometrial, and kidney. Aim for a BMI between 18.5–24.9 through balanced eating and regular physical activity (at least 150 minutes of moderate exercise weekly).Avoiding risky behaviorThis covers limiting alcohol (no more than one drink daily for women, two for men), practicing safe sex to reduce HPV and HIV transmission, avoiding needle sharing, and steering clear of unnecessary radiation or toxin exposure. These behaviors directly elevate risks for liver, cervical, and other cancers.Getting routine medical careRegular check-ups and age-appropriate screenings (mammograms, colonoscopies, Pap/HPV tests, low-dose CT for lung cancer) enable early detection when treatment is most effective. Discuss family history and personal risk factors with your doctor to create a tailored screening schedule.Maintaining a diet rich in fruits and vegetablesAim for at least five servings daily of colorful produce, whole grains, and legumes. These foods provide fiber, antioxidants, and phytochemicals that help protect cells from damage. Limit processed meats, sugary drinks, and ultra-processed foods, which are linked to higher colorectal and other cancer risks.Protecting your skin against cancerUltraviolet radiation from the sun and tanning beds is the primary cause of melanoma and other skin cancers. Use broad-spectrum SPF 30+ sunscreen daily, wear protective clothing and hats, seek shade during peak hours (10 a.m.–4 p.m.), and avoid indoor tanning. Monthly self-exams and annual dermatologist visits aid early detection.Getting vaccinated against hepatitis B and HPVThe hepatitis B vaccine prevents chronic liver infection that can lead to liver cancer. The HPV vaccine protects against strains responsible for nearly all cervical cancers plus many throat, anal, and genital cancers. Both are most effective when given before exposure, ideally in adolescence or early adulthood.#cancerprevention #cancerrisk #longevity #wellness #vaccination #smoking #vegetables #skincancer #smokingHow To Reach Dr. Joe Galati and his Team:For an on-line consultation or press inquiries, contact Teresa Reyes at 713-794-0700Dr. Galati's Newsletter Sign-UpLiver Specialists of TexasGet a Copy of Dr. Galati's BookDr. Galati on FacebookMessage Dr. Galati and his team Hosted on Acast. See acast.com/privacy for more information.

Sunday, June 21, 2026 Message: "What's in Your Basket?" Scripture: John 6:1-13 (CEB) By: Rev. Steve Price Scripture https://www.biblegateway.com/passage/?search=John%206%3A1-13&version=CEB Bulletin https://trinitygnv.org/s/Sunday-Bulletin-06-21-26-10AM.pdf Copyright: https://ccli.com/us/en/church-copyright-license Copyrighted content included in this webcast is used with license under one or more of the following: Christian Copyright Solutions WORSHIP cast Streaming License and PERFORM music License #7840 (to publicly perform and/or web stream any musical composition controlled by ASCAP, BMI, and SESAC), CVLI (Christian Video Licensing International) #503915511, CVLI ScreenVue License #502477880, CCLI Church Streaming & Podcast License #CSPL016331, CCLI Church Copyright License #1022361, and/or CCLI Church Rehearsal License #CRL011587.

Leave an Amazon Rating or Review for my New York Times Bestselling book, Make Money Easy! Check out the full episode: https://greatness.lnk.to/1940DM The paradigm shift hits fast. Dr. Gabrielle Lyon doesn't think we're over fat. We're under muscled. Skeletal muscle isn't just for lifting. It's your metabolic currency. Your body dispatches glucose through it, burns fat in it, and leans on it when illness or injury strike. The markers everyone defaults to, BMI and body fat percentage, are measuring the wrong thing entirely. More muscle doesn't automatically mean healthier muscle. Dr. Lyon explains the difference, and what actually matters. Sign up for the Greatness newsletter: http://www.greatness.com/newsletter Topics skeletal muscle health, muscle-centric medicine, Dr. Gabrielle Lyon, insulin resistance, metabolic health, obesity root cause, body composition, glucose disposal, BMI limitations, muscle mass and longevity Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about meals on repeat and whether eating the same foods over and over aids in weight loss. A new study claims that less variety in your diet is associated with better results, but is that the full picture? Jenn dives into the research, the numbers, and what they really mean, while questioning whether a 12-week study tells the whole story. Does sticking to the same meals set you up for long-term success, or could it backfire down the road? Tune in to hear Jenn break it all down and find out what she really thinks. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramKEYWORDS: Jenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Meals on Repeat, Weight Loss Research, Weight Loss Tips, Weight Loss, Meal Planning, Dietary Repetition, Caloric Stability, Calorie Tracking, Behavioral Weight Loss, MyFitnessPal, Food Logs, Weight Loss Program, Health Psychology, BMI, Overweight, Obesity, Meal Prep, Healthy Eating, Nutrition Tips, Wellness Coach, Diet Routine, Food Variety, Repetitive Meals, Self Control, Weekend Eating Habits, Weekday Eating Habits, Correlation Vs Causation, Diet Studies, Sustainable Weight Loss, Yo Yo Dieting, Healthy Habits, Food Tracking, Calorie Deviation, Diet Boredom, Real Food Coaching, Weight Loss Strategies, Nutrition Myths, Diet Research, Eating Patterns, Salad With A Side Of Fries, Jenn Trepeck, Health Coaching, Body Weight Management, Does Eating The Same Meals Help You Lose Weight, Benefits Of Meal Repetition For Weight Loss

Noah Guthrie first made a name for himself and his music when his YouTube cover songs were noticed by producers for the Ellen DeGeneres Show. He “won” a contract with Degeneres's fledgling record label which never manifested an actual album for the South Carolina singer-songwriter. But an appearance on America's Got Talent started the ball rolling for Guthrie. In that 2018 season of AGT he finished as a semifinalist. That soon placed him on the circuit of Today shows and Tonight shows, let to albums of originals and cover tunes and even landed him in the role of Roderick Meeks on the last season of the hit TV show Glee.  Today, Guthrie is promoting his new album Oddly Flexible, an astonishing record of deep, emotional journeys through life and love. It features the single, “Heavy,” which documents Noah's battle with his weight and self-image. The song has struck a nerve with fans who also deal with body image issues.  Noah joined Frank and Falls on Roots Music Rambler this week to talk about the song, the album, Noah's colorful journey and background. And yes, we talked about his beginnings on YouTube, including his amazing cover of LMFAO's “Sexy and I Know It.” Frank and Falls also clarify a recent controversy around the Manchester Music Fest, reassuring everyone the 2026 event is on as planned and Falls will see you there! This week's Pickin' the Grinnin' choices are two good ones! Frank likes Marfa and Falls brags on West Virginia singer-songwriter Austin Glaspell.  Watch the Episode on YouTube Download the episode and subscribe at rootsmusicrambler.com, watch the full episode on YouTube, or download wherever you get your podcasts.  Also be sure to help spread the love of the show with Roots Music Rambler's new merch, now available at rootsmusicrambler.com/store. Authentic t-shirts, hats and stickers are now available.  Buckle up for The Hoe-Down and the Throw-Down! It's a new episode of Roots Music Rambler. Notes and links:  Manchester Music Fest Manchester Enterprise piece on Parks buyout Noah Guthrie Online Noah Guthrie on Spotify Noah Guthrie on Instagram Noah Guthrie on YouTube Noah's audition on AGT The Roots Music Rambler Store Roots Music Rambler on YouTube Roots Music Rambler on Instagram Roots Music Rambler on TikTok Roots Music Rambler on Facebook Jason Falls on Instagram Jason Falls on TikTok Francesca Folinazzo on Instagram Pickin' the Grinnin' Choices Marfa on Spotify Austin Glaspell on Spotify Subscribe to Roots Music Rambler on YouTube, Spotify, Apple Podcasts, GoodPods or wherever you get your podcasts. Theme Music: Sheepskin & Beeswax by Genticorum; Copyright 2026 - Falls+Partners. All music on the program is licensed by ASCAP, BMI and SESAC. Roots Music Rambler is a member of the Americana Music Association. Learn more about your ad choices. Visit megaphone.fm/adchoices

Data centers might have a climate problem. With more than 80% of data centers worldwide in regions at high risk of drought, flooding, or wildfires. The implication of these trillions in investment being at elevated risk to weather related disasters could have some major downstream issues. Pluis, a dive into Accenture's earnings and the challenges facing the IT consulting industry.Listeners, we want your voices heard. The SEC is proposing that companies cut their regular reporting in half to two times a year. We think that's a mistake for individual investors.The SEC will take public comments on this issue until July 6th. We want to #savethe10q. Go to https://www.fool.com/investing/2026/06/15/motley-fool-save-the-10q/ to read our full statement and learn how to submit a public comment to the SEC.Companies discussed: META, TSMC, SPCX, TSLA, BMI, ITRI, VRT, ACN, EXLS, GLOB, IBMHost: Tyler CroweGuests: Matt Frankel, Jon QuastlEngineer: Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

In this enlightening episode, Dr. Cristina Castagnini sits down with Dr. Jenny Talbert to explore the pervasive issue of weight stigma within the healthcare system. Dr. Talbert shares her deeply personal journey of battling atypical anorexia and orthorexia while navigating the demands of medical training, revealing how the industry meant to heal can often cause profound harm. Together, they discuss the systemic barriers larger-bodied patients face—such as being denied necessary surgeries based on BMI—and offer a critical look at the current GLP-1 medication craze. Whether you are a patient who has felt dismissed by a doctor or a provider looking to offer more compassionate care, this conversation provides a roadmap for returning to body trust and authentic health. SHOW NOTES: Click here Follow me on Instagram @behind_the_bite_podcast Visit the website: www.behindthebitepodcast.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this enlightening episode, Dr. Cristina Castagnini sits down with Dr. Jenny Talbert to explore the pervasive issue of weight stigma within the healthcare system. Dr. Talbert shares her deeply personal journey of battling atypical anorexia and orthorexia while navigating the demands of medical training, revealing how the industry meant to heal can often cause profound harm. Together, they discuss the systemic barriers larger-bodied patients face—such as being denied necessary surgeries based on BMI—and offer a critical look at the current GLP-1 medication craze. Whether you are a patient who has felt dismissed by a doctor or a provider looking to offer more compassionate care, this conversation provides a roadmap for returning to body trust and authentic health. SHOW NOTES: Click here Follow me on Instagram @behind_the_bite_podcast Visit the website: www.behindthebitepodcast.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome back to When Words Fail, Music Freaks—the podcast where we explore how melody can lift us out of darkness. I'm your host, James Cox, a self‑declared “professional handicapped” advocate for mental‑health awareness, and today I'm honored to sit down with one of the most resilient, inventive, and inspiring musicians you'll ever meet: Peter Manning Robinson.From a three‑year‑old prodigy who instinctively knew the piano was his lifeline, to a survivor of sexual abuse and street homelessness, Peter has turned every hardship into a conduit for healing. He's an Emmy‑winning composer, a multi‑BMI award‑winner, and the creator of the groundbreaking Refractor Piano—a hybrid of hardware and software that re‑imagines what a piano can sound like in real time.In this conversation we'll:Uncover how a childhood trauma and a profound love for the piano became Peter's emotional equalizer.Hear the story behind his double‑helix concept albums, the raw grief of External Incursions, and the fire‑laden inspiration behind Excursions.Learn how a bout of debilitating tendinitis forced him to reinvent his technique, leading to a six‑month “martial‑arts” piano regimen that restored his playing and sparked an explosion of melodic, lyrical work.Dive into the birth of the Refractor Piano, a prism‑like instrument that refracts acoustic sound into entirely new textures—performed live, with no synths, no overdubs, just pure, spontaneous creation.Get Peter's brutally honest advice for anyone who feels their passion slipping away, and his mantra for staying present, grateful, and forever curious.Whether you're battling depression, searching for a new creative outlet, or simply love hearing how one artist turns adversity into art, this episode is a masterclass in resilience, innovation, and the unshakable power of music. Grab a cup of coffee (or tea—Peter's happy with both), settle in, and let the conversation remind you why, when words fail, music always speaks.

This episode breaks down gestational diabetes (new insulin resistance in pregnancy—not type 1 or 2), how insulin and glucose work, and why pregnancy naturally raises insulin resistance (but sometimes the pancreas can't keep up). It covers who's at higher risk (higher BMI, inactivity, prior GDM, certain ethnic groups, prior 9+ lb baby, PCOS, hypertension, heart disease) and how screening works at 24–28 weeks: the non-fasting 1-hour 50g test, followed by a fasting 3-hour 100g test if you “fail” (two elevated values = diagnosis). It explains why the test is a glucose “stress test,” alternatives like at-home fingersticks or CGM, and drink options (Glucola, Fresh Test, jelly beans). Finally, it outlines risks (C-section, shoulder dystocia, preeclampsia, baby hypoglycemia) and care differences between diet-controlled (deliver by 40+6) vs medication-controlled (NSTs/ultrasounds ~32 weeks, deliver ~39).00:00 Gestational Diabetes Overview00:52 How Insulin Works02:31 Risk Factors Explained03:20 Glucose Test Basics05:43 One Hour vs Three Hour07:06 At Home Monitoring Options09:42 Drink Alternatives13:52 Why It Matters Risks18:46 How Care Changes21:27 Final Recap Next Steps24:24 Closing Resources————

In this eye-opening episode, Dr. Scott Watier and Tommy Welling challenge the idea that the number on the scale is the best measure of metabolic progress, revealing why fasting is less about making the scale move and more about why it's moving. They break down the critical difference between being metabolically healthy at a higher weight versus metabolically at-risk at a normal weight, and why BMI alone misses the full picture. The hosts walk through five key markers to track alongside fasting — waist circumference, fasting glucose and insulin, triglyceride-to-HDL ratio, blood pressure, and visceral fat indicators — and explain how each one reflects real metabolic healing that the scale simply can't show. Listeners will come away understanding why consistency with fasting windows and simplified, protein-forward food choices accelerates cellular healing far more than chasing a daily weigh-in number. As a challenge this week, Dr. Scott and Tommy encourage listeners to measure their waist-to-height ratio, pull their most recent labs, and set one new scoreboard metric to track their true metabolic progress. ⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Resources and Downloads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Partner Links: Get your⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Get ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠25% off a Keto-Mojo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fasting For Life Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://www.levels.com/blog/what-can-weight-tell-you-about-your-metabolic-health

WORK WITH ME✅ Want a clear plan and someone to keep you on track?

Episode Title: Connected by Hope: How Sister Keli and Stephanie Bates Found Friendship Through Transplant Episode Description: What happens when two people who have walked through illness, uncertainty, and waiting find each other on the other side of survival? In this heartfelt episode of This Thing Called Life, host Andi Johnson welcomes Sister Keli and Stephanie Bates, whose connection began through transplant but became something much deeper—a sisterhood built on understanding, resilience, and hope. Together, they share their individual journeys through kidney disease, dialysis, setbacks, and ultimately transplantation. Through moments of heartbreak, perseverance, and unexpected friendship, Stephanie and Sister Keli reflect on what it means to keep showing up, trust the process, and find purpose in giving back. Their stories are a powerful reminder that healing doesn't happen alone—and sometimes the people who understand us best are the ones who have walked a similar road. Episode Highlights Host Andi Johnson welcomes Stephanie Bates and Sister Keli, two women whose lives became connected through their shared transplant journeys and commitment to supporting others. Stephanie reflects on how her health journey began after a traumatic cesarean delivery in 1999 that caused damage to her kidney. Years later, after noticing swelling in her leg, Stephanie sought medical care and was diagnosed with stage three kidney disease, beginning a long season of monitoring and treatment. From 2003 to 2013, she managed her condition through regular nephrology care before eventually beginning dialysis as her disease progressed. Stephanie shares the difficult but determined process of becoming transplant eligible, including being encouraged to lose weight in order to qualify. Through dedication and support, she achieved her health goals and was officially added to the transplant list in 2018. In 2019, Stephanie received her first kidney transplant, but unexpected complications during the COVID era eventually led her to undergo a second transplant in 2024. Sister Keli shares her own experience of learning her kidneys had progressed into end-stage renal disease (ESRD) and initially struggling to fully accept the seriousness of the diagnosis. She reflects on a turning point when conversations and encouragement from people around her helped her recognize the urgency of beginning treatment. Sister Keli started with peritoneal dialysis, later transitioning to hemodialysis after complications and challenges with treatment. Her journey included major life changes—including divorce and the eventual loss of a limb due to complications connected to inadequate dialysis treatment. Despite those setbacks, she remained committed to her health and continued pursuing transplant eligibility. Stephanie and Sister Keli describe meeting through a community connection event and immediately sensing a familiar understanding between them. What started as an invitation to volunteer quickly developed into a meaningful friendship rooted in shared experience. Both women speak openly about how transplant and dialysis journeys can feel isolating—and how finding someone who truly understands can change everything. They reflect on the emotional complexity of receiving a transplant call: excitement, disbelief, fear, gratitude, and awareness that another family experienced loss. The conversation highlights the emotional and physical realities of transplant while emphasizing the importance of hope, advocacy, and community support. Stephanie and Sister Keli encourage listeners to stay committed to treatment plans, ask questions, lean on others, and remember that healing often happens in connection with community. Key Takeaways: 1. Healing Is More Than Medical—It's Relational Recovery isn't only about procedures and appointments. Community, connection, and shared understanding can become powerful parts of the healing journey. 2. Small Decisions Can Create New Possibilities From staying committed to dialysis to making lifestyle changes for transplant eligibility, each step forward can open the door to life-changing opportunities. 3. Hope and Gratitude Can Coexist With Hardship Transplant journeys carry both joy and grief. Receiving a second chance at life often comes with deep appreciation for donors and renewed purpose moving forward. Tweetable Quotes “You have to be in a certain BMI to receive a transplant. The doctor connected me with weight loss people, we got a weight loss plan together, and I dropped that weight. Then less than six months after I dropped that weight, I was listed.” Stephanie Bates “I feel like the Lord started sending people to talk to me. You get a call from somebody that you haven't heard from in a while, and they have a message for you. And so these people over the weekend started talking to me, and I said, "Oh no,”  I said, "This is serious.” And so I reported, and they put me on peritoneal dialysis.” Sister Keli “This is why I'm here now, speaking out to people and letting them know, take your treatments seriously, don't cut off your treatments, don't skip your treatments, because the after effect of that? Sometimes you can't even come back from it.” Sister Keli “I'm like, something is familiar about her. And then I come to find her birthdays around my birthday, we just were familiar and able to link, but more than that, she understood where I had been, and I understood where she had been, and that was something I didn't have with any of my other friends.” Sister Keli “It (bond they share) creates a sense of like, “So there is someone who knows exactly what I'm going through.” Now our stories are not entirely the same. We've been through the same types of situations, the waiting process, “Is the kidney ever coming in?”, all the procedures, and all the testing. It feels daunting, it feels overwhelming.” Stephanie Bates Resources: Donatelifeky.org https://getoffthelist.org/ https://www.networkforhope.org/ https://www.networkforhope.org/about-us/ https://www.networkforhope.org/stories-of-hope/ https://www.facebook.com/NetworkForHopeOPO https://www.youtube.com/@NetworkforHope. https://aopo.org/ RegisterMe.org/NetworkforHope

In this episode of the TCOYD Podcast, Dr. Edelman and Dr. Pettus are joined by pediatric endocrinologist Dr. Jamie Wood, medical director of pediatric diabetes at Rainbow Babies & Children's Hospital and an investigator on the INHALE-1 trial, to talk through inhaled insulin in kids and where it fits in real-world pediatric care.The conversation focuses on the recent approval of Afrezza for children as young as six, and what the INHALE-1 trial actually showed. Dr. Wood walks through the study design, A1C results, lung-function and safety data, and the practical aspects of dosing inhaled insulin in a pediatric population. Rather than positioning it as a replacement for injections or pumps, the discussion centers on finding the right fit for each child's needs, from the newly diagnosed kid with a needle phobia to the teen trying to dose discreetly during a 20-minute school lunch.Dr. E, Dr. P, and Dr. Wood also discuss the everyday realities that shape how this option is used, including the set-dose cartridge sizes, a titration approach refined in clinic, and how families are mixing and matching tools alongside automated insulin delivery. The takeaway is encouraging: there are more options than ever for managing mealtime insulin in kids, and this one may help fill some of the gaps left by injections and pumps.Key Topics • The recent approval of inhaled insulin for children as young as six • How the INHALE-1 pediatric trial was designed • A1C results and what the primary endpoint analysis showed • Continuous glucose monitor (CGM) metrics across the two groups • Lung-function (FEV1) monitoring and pediatric safety • Weight and body mass index (BMI) findings • Why mealtime dosing is a leading unmet need in pediatric type 1 diabetes (T1D) • The set-dose cartridge approach and how it reframes meal sizes • A real-world titration method for inhaled insulin • Managing cough and other practical considerations • Needle phobia and the kids who struggle most with injections • Using inhaled insulin alongside automated insulin delivery (AID) systems • What's coming next, including a smaller cartridge dose and a new-onset trial Subscribe for practical diabetes management tips, technology updates, and treatment breakthroughs that help people with diabetes live healthier, more flexible lives.More diabetes resources:Website: tcoyd.orgBlog: tcoyd.org/blogPodcast: tcoydthepodcast.transistor.fmInstagram: / tcoydFacebook: / tcoydStay connected! Sign up for our monthly newsletter here!Support TCOYD's educational programs: tcoyd.org/donate ★ Support this podcast ★

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Sunday, June 14, 2026 Message: "Ode to the Master Gardener" Scripture: 1 Corinthians 3:5-9, 21-23 By: Rev. Steve Price Scripture https://www.biblegateway.com/passage/?search=1%20Corinthians%203%3A5-9%2C%2021-23&version=CEB Bulletins https://trinitygnv.org/s/Sunday-Bulletins-06-14-26-8AM-e5my.pdf https://trinitygnv.org/s/Sunday-Bulletins-06-14-26-8AM-930AM-WEB.pdf https://trinitygnv.org/s/Sunday-Bulletins-06-14-26-8AM-11AM.pdf Copyright: https://ccli.com/us/en/church-copyright-license Copyrighted content included in this webcast is used with license under one or more of the following: Christian Copyright Solutions WORSHIP cast Streaming License and PERFORM music License #7840 (to publicly perform and/or web stream any musical composition controlled by ASCAP, BMI, and SESAC), CVLI (Christian Video Licensing International) #503915511, CVLI ScreenVue License #502477880, CCLI Church Streaming & Podcast License #CSPL016331, CCLI Church Copyright License #1022361, and/or CCLI Church Rehearsal License #CRL011587.

Season 6, Episode 756: Video Version. Featuring Shoshanna Blanca, aka Jesus Christ Pornstar,  Reclaiming Sexuality as Sacred: Spirituality, Psychedelics, and Breaking Religious Taboos. affiliate book link "Eve's Blessing: Uncovering the Lost Pleasure Behind Female Pain" When Mary Magdalene Became a Mirror for Sacred Sexuality Affiliate link Pearl Toys from Kiiroo: Get 10% OFF ENTIRE ORDER (min. purchase $69, no usage limits) with affiliate code RUANWILLOW10 on pleasure sex toys at https://www.kiiroo.com/ https://offers.feeliate.com/to92wTJh Discission Topics/Chapters: Shoshanna Blanca, From Feminist Writer to Erotic Artist Bridging Sexuality and Spirituality Through Psychedelics Divine Creativity and Sexual Shame Culture Reframing Sex Work as Spiritual Art Jesus Would Listen to Sex Workers Biblical Interpretation and Religious Judgment Reinterpreting Genesis: Beyond the Eve Curse God's Gender and Universal Consciousness Orgasmic Prayers and Reclaiming Pleasure Modern Dating Culture and the Whores Revolution Bridging Porn and Social Media Culture Men's Misconceptions about and the Perpetuating Falsehoods About Biological Clocks Preparing for Psychedelic Ceremonies and Intentions Teshuva: Returning to Original Virtue Women's Suffering and the Need for Reverence Finding Freedom Through Breath and Spirit Body Innocence and Pleasure as Birthright Takeaways: • Psychedelic experiences can fundamentally reshape views on sexuality and spirituality. Shoshana's ceremony-induced rebirth experiences directly motivated her to reframe sex work and erotic expression as spiritual practices rather than taboo activities. • Religious symbolism in sexual content triggers deeper cultural anxiety than the sexuality itself. The backlash against her work centered more on the use of Jesus and Mary Magdalene imagery than the explicit content, revealing how religious institutions weaponize shame around sexuality. • Sex workers and erotic performers position themselves as spiritual healers, not moral transgressors. Let's curb our judgement! By redefining their work through a sacred lens, they challenge the foundational shame narratives that justify social stigma and argue this reframing could revolutionize how society treats sex workers, and sexuality. Guest Bio: Shoshanna Blanca, also known as Jesus Christ Pornstar, is an erotic performance artist and adult star best known for Christian and Jewish-inspired content including The Second Cumming—a series of vlogs and performances telling the story of Jesus and Mary Magdalene through a psychedelic lens—and Uncovering Eve, a collection of images, videos, and verses exploring women and womanhood in the Bible. After a decade as a feminist writer and sex educator, she made OnlyFans her art gallery to provide a visual companion to her award-winning book Eve's Blessing: Uncovering the Lost Pleasure Behind Female Pain. Since then, she's released a variety of female-friendly solo content for Ersties, MakeLoveNotPorn, and Pornhub, including an "ADHD Masturbation" series where she describes her fantasies and tangential thoughts while self-pleasuring and "Hysterical Literature Bible Readings," where she reads from the Bible and other sacred texts while using a Hitachi Magic Wand. She's also a model with photographs published in many magazines and an advocate for body positivity. As one of those people who looks "overweight" and "plus-size" on paper but skinny in person, she aims to dismantle the ridiculous sizing and BMI charts that have become false gods. Through her thought-provoking pornography and social media presence, she's starting a whores revolution, encouraging whores of all sorts to rise up, remember Jesus already saved a spot for them in heaven, and get too loud and proud for people to label them damaged goods—or for whorephobic fuckboys to label them hookup material but not marriage material. She popularized and advocates radical Christianity, a belief system that preaches zero divine laws except: Be who you are. Links for Shoshanna Blanca: https://linktr.ee/shoshannalovesjesus https://x.com/shoshannablanca https://onlyfans.com/shoshannablanca https://onlyfans.com/uncoveringeve https://makelovenotporn.tv/makelovenotpornstars/shoshannablanca/videos https://www.amazon.com/Eves-Blessing-Uncovering-Pleasure-Behind/dp/1509566171/   Support the show Ruan Willow, Podcast host and author, join to get her newsletters https://subscribepage.io/ruanwillow All Ruan's LInks: https://linktr.ee/RuanWillow

Trump turns 80. Musk goes trillionaire. Maine's Dem frontrunner had a Nazi tattoo. In this episode: • Trump cancels Iran air strike — no one told Iran • Jay Clayton named DNI over actually qualified Bill Py • Todd Blanch nominated as permanent AG: commits one felony a day for Trump • $70 billion for ICE — body cameras not included • SpaceX IPO: the largest in stock market history — Musk becomes the world's first trillionaire • 1 million AI data centers in orbit. 1 million Optimus humanoid robots. The endgame. • Trump visited 22 medical specialists — zero psychiatrists • Trump turns 80 and gains weight: BMI 29.9, just under "obese" • Trumpflation is official • Graham Platner leads Susan Collins by 9 points in Maine • Platner's skull-and-bones tattoo turned out to be a Nazi SS symbol • Platner's digital trail: racism, misogyny, and trivialization of rape • NYT hints Platner may have been physically abusive toward women Key figures covered: Donald Trump, Elon Musk, Todd Blanch, Jay Clayton, Graham Platner, Susan Collins, Pete Hegseth, Bill Gates, Steven Miller

Timestamps : 00:00 — Intro — Welcome to the Holistic Kids Show 00:20 —  The Childhood Obesity Crisis: The Numbers 01:14 — Guest Introduction: Ashley Koff, RD 02:12 — Ashley's Personal Story & What Drove Her Mission 04:34 — Rethinking Weight: It's a Signal, Not a Sentence 05:15 — Introducing Your Best Shot & Weight Health 06:07 — Understanding Hormones: GLP-1, GIP, CCK & PYY Explained Simply 08:15 — How Gut Hormones Control Blood Sugar, Appetite & Bone Health 10:16 — The Gut-Hormone Connection: Why Your Microbiome Matters 11:05 — Can Kids Take GLP-1 Hormones? 11:25 — Ozempic, Wegovy & GLP-1 Medications Explained 13:40 — GLP-1 Medications Approved for Kids 10+ — What Parents Must Know 15:28 — 3 Daily Habits to Naturally Balance Your Hormones 17:21 — Habit #2: Eat Like a Race Car — Fueling at the Right Times 18:04 — Habit #3: Move After Every Meal — Why 7 Minutes Matters 22:03 — "Better, Not Perfect" — What That Really Means for Teens 25:00 — The One Nutrition Rule Every Kid Should Know 29:49 — Where to Find Ashley Koff & Her Resources One in five US children lives with obesity — but are we asking the right questions? In this powerful episode, the Holistic Kids crew sits down with Ashley Koff, RD, USA Today bestselling author of Your Best Shot and a leading weight health practitioner with over 25 years of experience. Ashley flips the script on how we talk about weight with kids — moving away from diets, BMI, and body shame, and toward understanding what the body is actually telling us. She explains how hormones like GLP-1, GIP, and PYY are made in the gut lining, why antibiotics and medications can disrupt them for years, and what that means for growing bodies. The conversation also tackles the rising use of GLP-1 medications (like Ozempic and Wegovy) in kids as young as 10 — what the research says, what parents and teens should know, and why these medications are a tool, not a solution on their own. In this episode, you'll learn: Why weight is a signal, not a sentence What GLP-1, GIP, and gut hormones actually do — explained simply How antibiotics and medications affect your hormones for years The truth about GLP-1 medications for kids and teens 3 daily habits to naturally support hormone balance Why BMI is a flawed measure — and what to look at instead The "race car" nutrition approach that keeps your body running better What "better, not perfect" really means for teenagers Guest: Ashley Koff, RD — Founder of The Better Nutrition Program, author of Your Best Shot, recognized by CNN as one of the Top 100 Health Makers.

Burn Fat While You Sleep, Boost Metabolism & Fast the Smart Way with guest expert Dr. William Li #64What if everything you've been told about metabolism, fat, and weight loss is wrong? In this episode, Samantha sits down with Dr. William Li for a second conversation in season 2 (Check out Episode #62, if you missed it - and Season 1 Episode #14 as well!).Dr. Li dismantles everything you thought you knew about metabolism, visceral fat, and intermittent fasting — revealing the science-backed strategies that let your body burn dangerous fat while you sleep, eat, and live your life.Dr. Li is an internationally renowned physician-scientist, president of the Angiogenesis Foundation, and New York Times bestselling author of Eat to Beat Your Diet — to expose the myths that have kept so many women stuck in a cycle of dieting, frustration, and self-blame.Spoiler: your metabolism is not broken. It never was.From the newly discovered science proving that human metabolism stays rock-stable from age 20 to 60, to the hidden danger of "skinny fat" and its shocking link to breast cancer, to the brilliantly simple 12-hour fasting protocol Dr. Li himself follows every day — this episode is a masterclass in working with your body instead of against it. Plus, the true origin story of the famous 16:8 intermittent fasting method that no one is talking about.WHAT YOU'LL LEARN:Your metabolism is NOT slowing down: Learn the findings from a landmark study of 6,000 people that completely rewrites what we thought we knew about metabolism — and where the real culprit actually lives.Fat is a hormone-producing organ: Discover why healthy fat is essential to your metabolic function, and what happens to your hormones when it starts to grow out of control.Excess fat behaves like a tumor: Find out why Dr. Li says too much body fat follows the same dangerous playbook as cancer — and why that makes chronic inflammation so much more urgent to address.Skinny fat is a real and serious risk: Learn what a 13-year Cornell study found when it scanned nearly 3,500 normal-weight women — and why the results are a wake-up call for women who think they're in the clear.Foods that burn fat at the cellular level: Discover which everyday grocery store foods contain natural bioactives that work against fat growth — and how they do it without you changing everything on your plate.The tape measure test: Find out why your waistline tells a more accurate story about your health than your BMI, your scale, or your body size — and how to use it at home for free.Why 12 hours of fasting is enough: Learn the surprisingly achievable protocol Dr. Li follows himself every single day — and why the research says you don't need to go longer to see real results.The truth about 16:8: Discover the origin story of the most popular intermittent fasting method — and why its famous time window has almost nothing to do with human science.Insulin is the metabolic switch: Understand the simple biological reason your body burns fat while you sleep — and how the timing of your last meal determines how hard it works overnight.Ultra-lean is not ultra-safe: Find out why the medical literature puts extreme leanness in the same dangerous category as extreme obesity — and what that means for how we define a healthy goal.About Our GuestDr. William Li is an internationally renowned physician, scientist, researcher, and author whose work has impacted over 70 diseases, including cancer, diabetes, and cardiovascular disease. He is the founder and president of the Angiogenesis Foundation and is best known for his groundbreaking TED Talk, Can We Eat to Starve Cancer?, which has been viewed by millions worldwide. He is the New York Times bestselling author of Eat to Beat Disease and Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, and Live Longer.

Dr. Liz Graves didn't set out to become a doctor. She discovered chiropractic as a patient, fell in love with its foundational philosophy that the body heals from the inside out, and built a career around that principle. Today, as the founder of Back 2 Real Food, she helps people restore their metabolic health through food, cyclic nutrition strategies, and targeted amino acid therapy — without relying on willpower, calorie restriction alone, or one-size-fits-all dieting.In this episode, Dr. Tara Perry sits down with Dr. Graves for a wide-ranging conversation on why so many people are doing "everything right" and still can't lose weight, what the modern food system is doing to our metabolism, and the counterintuitive strategies that actually work.Key Takeaways:The real reason diets stop working (00:07:00) — Every time you diet without recovery, your body adapts to living on less, slowing your metabolism over time. Dr. Graves explains her cyclic approach: a structured window of fat loss followed by a deliberate high-calorie phase that trains the body to metabolize more, not less.Seed oils are the #1 offender in your diet (00:16:44) — Vegetable, canola, sunflower, and safflower oils disrupt cell walls, cause inflammation at the cellular level, and impair mitochondrial function. Removing them is the first and fastest win Dr. Graves makes with every new client.Three foods worth adding right now (00:19:41) — Healthy natural fats (animal fats, olive oil, coconut oil), quality mineral-rich sea salt, and more whole foods without a label. Small additions that compound into meaningful change.Know your farmer (00:21:49) — Pesticide load, not the food itself, is driving the explosion in leaky gut, celiac, and autoimmune conditions. Dr. Graves recommends the Weston A. Price Foundation as a starting point for finding local farmers and co-ops, and makes the case that buying direct is often cheaper than buying organic at a grocery store.Targeted amino acid therapy changed everything (00:26:56) — Most people have never worked with a practitioner who assesses neurotransmitter imbalances and uses amino acids to correct them. Dr. Graves explains how depleted GABA, serotonin, and dopamine pathways fuel emotional eating, overwhelm, and burnout — and how replenishing them through targeted therapy gives people the neurological resilience to stay on course.Cortisol, stress, and weight retention (00:32:41) — Chronic low-grade stress (email, notifications, relentless demands) keeps the body in protective mode, holding weight and suppressing metabolic function. Dr. Graves connects the modern stress environment to the ancestral body we're still living in, and explains why supporting the brain matters as much as fixing the food.Body composition over the scale (00:58:06) — Dr. Graves uses body composition testing (muscle, fat, water, bone) rather than BMI or scale weight to track real progress. She shares the story of a five-foot-one woman with 105 pounds of muscle who technically "should" weigh 100 pounds — and why that framing is misleading and discouraging.What results actually look like (00:47:24) — On Dr. Graves' six-week protocol, most people lose about 10 pounds and drop one clothing size. On the nine-week plan, 15 to 30 pounds and two clothing sizes. She describes it as achieving six to nine months of focused progress in six to nine weeks — structured and demanding while you're in it, but consistently described as the easiest thing clients ever did when they look back.Ready to take your own next step?Visit calendly.com/consulttara/consult to book your free customized consultation with Dr. Tara Perry and get your GPS map — the coordinates for where you are now and where you want to go.

We push back on the idea that obstetrics “deserves” a malpractice crisis and explain how bad incentives and junk science can turn normal evidence-based care into courtroom blame. We also break down a few widely shared clinical myths and new research so we can practice with clearer eyes and less narrative noise.• placental grading on ultrasound as low-value data with poor predictive power and high reader variability • how malpractice commentary can seed plaintiff-friendly arguments against evidence-based off-label use • why blaming misoprostol or “high-dose” oxytocin oversimplifies multifactorial outcomes • quality improvement bundles as useful tools but weak proof without controls or causal clarity • how massive verdicts and paid expert testimony can clash with modern science on cerebral palsy and HIE • the FAA's five hazardous attitudes and practical antidotes for high-stakes clinical work • new data on LEEP versus cold knife cone for CIN, recurrence, HPV clearance, and access tradeoffs • genetics and BMI as major drivers of gut microbiome patterns, not influencer narratives • what a 1993 Doppler trial can and cannot prove, plus why replication changes conclusions Be sure to check out thinkingaboutobgyn.com for more information and be sure to follow us on Instagram.0:00 Welcome And Season Update1:15 Placental Grading Myth On Ultrasound6:44 Calling Out A Malpractice Influencer14:06 The 2011 Policy Bundle Examined23:20 What Drives The OB Malpractice Crisis30:00 How Mega Verdicts Get Made36:59 Five Hazardous Attitudes From Aviation44:31 LEEP Versus Cone For CIN48:04 Genetics And The Gut Microbiome52:17 Does Doppler Ultrasound Harm Babies?1:00:37 Recommendations And ClosingFollow us on Instagram @thinkingaboutobgyn.

Dr. Spencer and Karl Nadolsky sit down with David W, a nurse practitioner and one of the actual patients enrolled in the Triumph 1 retatrutide phase 3 trial, to break down the data that was just presented at the American Diabetes Association conference and explain why everyone in obesity medicine is paying very close attention. In this episode they cover what retatrutide actually is and why adding glucagon agonism to the GLP-1 and GIP dual agonism of tirzepatide creates a meaningfully different drug with direct effects on liver lipid metabolism, insulin sensitivity, blood pressure, and fat catabolism that you do not see with semaglutide or tirzepatide alone, what David's personal experience in the 12 milligram arm looked like from dose escalation through steady state including the GI side effects that faded by month seven and the heartburn that a low dose PPI fixed quickly, how David went from 240 pounds and a BMI of 35 down to 167 pounds by the end of the trial representing roughly 30 percent weight loss which is right at the trial average, what the Triumph 1 obesity trial found at 80 weeks with the nine and 12 milligram doses delivering nearly 26 and 28 percent average weight loss respectively and almost half of patients on the highest dose losing 30 percent or more, why the 104 week extension data showing patients who stayed on 12 milligrams reaching 30.3 percent average weight loss is being compared to bariatric surgery outcomes, what the Transcend type 2 diabetes trial showed with average A1C dropping to 5.9 percent on the 12 milligram dose in patients who were on no other diabetes medication, why the 41 percent triglyceride reduction and 20 percent LDL reduction are particularly interesting given that the mechanism appears to involve multiple pathways in the liver that tirzepatide and semaglutide do not touch, what the 70 percent reduction in WOMAC knee arthritis pain scores and 60 percent reduction in sleep apnea events mean for patients who have been told their only option is surgery, how Spencer plans to use retatrutide clinically once it is approved and which patients he thinks are the right candidates, why the gray market research peptide version currently circulating is something both doctors strongly advise against, and what Triumph 2 and Triumph 3 are measuring and when that data is expected. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A fitness creator posted about a woman's body, called it obesity, and the internet went into full meltdown — but was he wrong? We react to the viral post that racked up 1.5 million views, break down what "obese" actually means, and explain why BMI is an outdated tool that was never designed to measure your health. We also get into what actually matters — body fat percentage, where you carry your weight, and the waist-to-height ratio you should actually be paying attention to. Join this channel to get access to perks:https://www.youtube.com/channel/UC_8nonbBsA-mTli1KLlHlrA/joinWork with JeanineBook a free consult https://bit.ly/4dUHYZeMike's YouTube Channel:  @escoelitemindsetMike's Instagram: https://www.instagram.com/@escoelitemindsetSupport our Sponsors1UP Nutrition Code: JEANINEhttps://1upnutrition.com/JEANINEHRT & Peptides (Tell them Jeanine Escobar when filling out ntake)https://www.vitabella.comMegaFit Meals - Code Jeanine10 https://megafitmeals.rfrl.co/p75q7Built Bar Code: MRSCEOJhttps://builtbar.com?baapp=MRSCEOJSupport us by following on Social MediaAmazon Storefront: https://www.amazon.com/shop/mrsceo_jLTK Fashion Links: https://www.shopLTK.com/explore/MrsCEO_JShopmy https://shopmy.us/shop/mrsceoj?Section_id=1519253&tab=collectionsInstagram: https://instagram.com/mrsceo_jInstagram: https://instagram.com/candidly_withcoffeeWeight Loss IG: https://instagram.com/@coach.jeanineescobarTikTok: https://www.tiktok.com/@mrsceo_j

BMI has been treated like a health report card… but it was never designed for that job. In this episode, we unpack where Body Mass Index (BMI) actually came from, why it was created, and how it's being misapplied…especially in athletic populations like runners. If you've ever been told you're “overweight” based on BMI despite training hard, fueling well, and feeling strong… this one's for you. We'll talk about: The history of BMI and why it was never meant to assess individual health Why BMI fails to account for muscle mass, performance, and physiology How endurance athletes often fall into “higher” BMI categories despite being metabolically healthy The harm of equating thinness with health especially in running culture What actually does matter when assessing health and performance as a runner This episode is your reminder: you are not a ratio. And your healthiest running body might not fit neatly into a chart. This episode originally aired May 8, 2023. Click here to try Legion Protein Powder for yourself use my code RUNNERGIRL for buy one get one 50% off and free shipping on your first order! Don't forget to follow me on Instagram @runnergirldietitian

The study you should read this week A 2016 meta-analysis from the CMAJ pulled together 46 prospective cohort studies — 1.2 million people, 78,000 deaths. The finding: for every 10 beats per minute higher your resting heart rate sits, your all-cause mortality risk goes up about 9 per cent. Linear from 45 bpm upward, no point where lower stops being better. Independent of blood pressure, smoking, BMI, cholesterol, diabetes, and physical activity. Resting heart rate is carrying its own signal. Plus what to do with this if you race, ride high volume, or train time-capped — and why the adaptations that lower your resting heart rate are the same adaptations that predict a longer, healthier life. Study: Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. CMAJ 2016;188(3):E53–E63. DOI: 10.1503/cmaj.150535 Links: YouTube companion: Cyclist Over 50? Your Fitness Can't Tell You This. Guided is live — two coaches, weekly review, my read behind every plan: https://go.semiprocycling.com/go/btsmfgDaily cycling intelligence from SEMIPRO CYCLING, produced with AI-assisted research, scripting, and synthetic voice.

This episode is brought to you by LMNT, Fatty15, and Caldera Lab. What if obesity isn't a willpower problem at all? In this deeply eye-opening conversation, Chase sits down with bariatric surgeon and obesity medicine specialist Dr. Betsy Dovec, MD to unpack the science, psychology, and stigma surrounding obesity in America today. From GLP-1 medications like Ozempic and Mounjaro to bariatric surgery, emotional eating, food addiction, metabolic dysfunction, and the failures of fad diets, this episode challenges nearly everything we think we know about weight loss. Whether you're someone struggling with weight, supporting a loved one, or simply curious about the future of metabolic health, this conversation offers nuance, compassion, and hard truths that could completely reshape your understanding of obesity and modern wellness. IN THIS EPISODE YOU WILL LEARN Why Dr. Dovec believes obesity is primarily biological — not a lack of discipline The hidden role trauma and emotional safety can play in weight gain How bariatric surgery changes hormones, hunger, and "food noise" The truth about Ozempic, Wegovy, Mounjaro, and long-term GLP-1 use Why most people regain weight after stopping GLP-1 medications The difference between gastric bypass and gastric sleeve surgery Why visceral fat is more dangerous than the number on the scale How obesity impacts cardiovascular disease, diabetes, fatty liver, and longevity The surprising reason BMI may be one of the worst health markers Why women account for nearly 85% of bariatric surgery patients How sugar and ultra-processed foods are driving the obesity epidemic What long-term success after bariatric surgery actually requires The psychological side of transformation and behavior change Why "food noise" may be one of the biggest hidden barriers to weight loss How bariatric surgery and GLP-1s may work best together The future of weight loss medicine, surgery, and employer healthcare coverage Follow Betsy @drdovec Follow Chase @chase_chewning ----- 00:00 — Is Obesity a Willpower Problem or a Biological Problem? 04:40 — When Should Someone Consider Bariatric Surgery? 08:00 — Trauma, Emotional Eating & Feeling Unsafe in the Body 14:20 — Why Obesity Is More Complex Than Calories In vs. Calories Out 15:40 — Why Men Wait Too Long to Address Their Health 17:42 — Bariatric Surgery Misconceptions & Who Actually Qualifies 19:00 — How Bariatric Surgery Immediately Improves Diabetes 20:40 — Why BMI Is a Flawed Health Marker 23:00 — Visceral Fat, Fatty Liver Disease & Sugar Addiction 27:00 — Is Obesity Truly Reversible? 29:20 — Why Gastric Bypass Is Still the "Gold Standard" 31:55 — How Gastric Bypass Surgery Actually Works 35:00 — Nutrient Absorption & Supplements After Surgery 37:00 — What Daily Life Looks Like After Bariatric Surgery 42:00 — Food Noise, Hunger Hormones & Feeling Full for the First Time 45:00 — Risks, Complications & Safety of Bariatric Surgery 49:45 — Insurance Coverage, Costs & Why Employers Are Paying for Surgery 54:30 — Long-Term Outcomes & Lifespan Benefits 57:00 — Eating Disorders, Addiction Transfer & Alcohol After Surgery 01:02:00 — Why Dr. Dovec Prioritizes Lower Carb Nutrition 01:05:00 — The Ethics of the Weight Loss Industry 01:10:00 — GLP-1 Medications vs. Bariatric Surgery 01:15:00 — Why Bariatric Surgery Numbers Are Falling 01:20:00 — Rapid Fire: Ozempic, Body Positivity & Discipline 01:25:00 — Parenting, Childhood Obesity & The Future of Weight Loss 01:29:00 — What "Ever Forward" Means to Dr. Dovec ----- Episode resources: Watch and subscribe on YouTube Learn more at BodyByBariatrics.com FREE variety sample pack of LMNT electrolytes  Additional 15% off Fatty15 with code EVERFORWARD 20% off Caldera Lab men's skincare with code EVERFORWARD